The Power of Partnerships
EIN Presswire reports that POP Biotechnologies - a UB spinoff biopharmaceutical startup - announced the commencement of dosing of the shingles vaccine “EuHZV” in collaboration with Korean partner, EuBiologics Co. Ltd. in a Phase 1 clinical study in Korea.
The Phase 3 clinical trial of EuCorVac-19, ielded positive interim results. Conducted in the Philippines with around 2,600 adults, the trial demonstrated that EuCorVac-19 achieved superior antibody immunogenicity compared to a WHO-authorized adenoviral vector vaccine, successfully meeting the trial's primary endpoint.
POP BIO co-founder Jonathan Lovell shares, “This is the third such vaccine to enter human testing, which solidifies the versatility of the platform technology and reflects our dedication to delivering next-generation vaccines to improve human health.”
Read the full story here.